Preferences and Support for Psychedelic Policies and Practices Among Those Using Psychedelics.
Daniel J. Kruger, Julie Barron, Moss Herberholz, Kevin F. Boehnke
Journal of Psychoactive Drugs 2023 DOI: 10.1080/02791072.2023.2228784 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Cross-sectional survey Peer reviewed |
|---|---|
| Sample size | 1,221 |
| Population | People using psychedelics naturalistically, mostly from the State of Michigan |
| Keywords | Psychedelics Community-based research Policy Preferences |
| Citations | 4 |
| Key findings | Three-quarters of participants supported decriminalization and legalization, and strongly favored legal personal cultivation and possession of psychedelic plants and fungi, with more support for natural over synthetic substances and for therapeutic support over none. |
Abstract
Legal, scientific, and social landscapes for psychedelics are changing rapidly. Differences of opinion exist among key stakeholders regarding regulatory control, models of provisioning psychedelic therapy, and medicalization, decriminalization, and/or legalization policies. We assessed the policy preferences of people using psychedelics naturalistically (N = 1221) to understand how they aligned and differed with institutional entities and existing psychedelic policies. Three quarters of participants would support decriminalization and legalization. On average, participants strongly supported individuals being legally able to grow and possess psychedelic plants and/or fungi for personal consumption. Trends included more support for natural over synthetic substances, self-production and consumption over gifting, gifting over sales, and administration of psychedelics with therapeutic support than without therapeutic support. Participants were concerned about pharmaceutical-like policy models, including patents of natural and synthetic psychedelic compounds. Participants were mostly from the State of Michigan, though geographical differences were minor. Those who identified as a psychedelic guide, educator, or therapist had small yet extensive differences from those who did not. As psychedelic liberalization continues to advance, it is critical for policymakers to consider these preferences to ensure laws provide safe and equitable access to these substances and appropriate medical support for their use.
Citations in the library
Cited by 5
- State Cannabis and Psychedelic Legislation and Microdosing Interest in the US. JAMA Health Forum June 7, 2024
- Pattern of psychedelic substance use: a comparison between populations in Spain and South America using the Psychedelic Use Scale (PUS) Current Psychology November 21, 2024
- Priorities for psychedelic research among people who use psychedelics. Journal of Psychiatric Research June 2, 2026
- Mixed-Methods Study of Use and Attitudes About Psychedelics for Therapeutic Purposes Among Low-Income U.S. Veterans Nationally. Journal of Psychoactive Drugs March 24, 2025
- Perceptions of Psychedelic Decriminalization: Findings from a Community Survey of People Who Use Psychedelics Social Sciences August 23, 2026
Cites 22
- Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder JAMA Psychiatry November 4, 2020
- Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study Journal of Psychopharmacology January 13, 2015
- Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression. New England Journal of Medicine November 3, 2022
- MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nature Medicine June 1, 2021
- Long-term follow-up of psilocybin-facilitated smoking cessation The American Journal of Drug and Alcohol Abuse July 21, 2016
and 17 more in the library